Anticancer Activity of Melittin-Containing Bee Venom Fraction Against Glioblastoma Cells In Vitro
International Journal of Molecular Sciences · 07.03.2025 · 26 (6) · 2376
DOI: 10.3390/ijms26062376 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.03.2025. Verfasst von Agata Małek und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Chemistry, Medical University of Lublin, 20-093 Lublin, Poland. Hauptthemen laut MEDLINE: Melitten, Glioblastoma, Bee Venoms, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Center, National Science Centre, Poland.
Abstract (Originalsprache)
Previous observations indicating a lower incidence of various types of cancer in beekeepers suggest that greater exposure to stings reduces the risk of cancer development. However, it is not known which of the active compounds of the bee venom (BV) may be responsible for the observed properties. The aim of this study is to evaluate the anti-glioblastoma effect of the main BV fractions. In addition, the effect of BV fractions on the activity of matrix metalloproteinases 2 and 9 (MMP-2 and MMP-9) was assessed. Commercially available BV was divided into three fractions containing one of the main BV components: apamin (fraction #1), phospholipase A2 (fraction #2), or melittin (fraction #3). The viability of glioblastoma lines (LN18 and LN229) compared to a physiological line (human MO3.13) was assessed using the MTT. MMP-2 and MMP-9 activity was assessed using gelatin zymography. Tissue inhibitors of metalloproteinases 1 and 2 (TIMP-1 and TIMP-2) levels in cell culture media were measured with the ELISA method. The fraction containing apamin did not show cytotoxic activity up to a concentration of 100 µg/mL. The fraction containing phospholipase A2 partially reduced the cells’ viability at a concentration of 100 µg/mL. The greatest activity was demonstrated by the melittin-containing fraction which completely reduced the viability of glioma cells from a concentration of 2.5 μg/mL and inhibited the activity of the assessed metalloproteinases in a dose-dependent manner. After 72 h of incubation, the highest concentrations of TIMP-1 and TIMP-2 (approximately 150 ng/mL and 100 ng/mL, respectively) were observed in the LN229 line. In all tested lines, fraction #3, crude BV, and melittin reduced the secretion of both inhibitors into the medium in a dose-dependent manner. The melittin-containing fraction possessed anti-glioma properties in vitro, suggesting that melittin may be the main anticancer compound of BV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Chemistry, Medical University of Lublin, 20-093 Lublin, Poland.
- Department of Analytical Chemistry, Medical University of Lublin, 20-093 Lublin, Poland.
- Department of Molecular Biology and Translational Research, Institute of Rural Health, 20-090 Lublin, Poland.
- World Institute for Family Health, Calisia University, 62-800 Kalisz, Poland.
ORCID-Profile: Agata Małek, Maciej Strzemski, Jacek Kurzepa
Förderung
- National Science Center
- National Science Centre, Poland
Zitieren
APA
Małek, A., Strzemski, M., Kapka-Skrzypczak, L., & Kurzepa, J. (2025). Anticancer Activity of Melittin-Containing Bee Venom Fraction Against Glioblastoma Cells In Vitro. International Journal of Molecular Sciences, 26(6), 2376. https://doi.org/10.3390/ijms26062376
Vancouver
Małek A, Strzemski M, Kapka-Skrzypczak L, Kurzepa J. Anticancer Activity of Melittin-Containing Bee Venom Fraction Against Glioblastoma Cells In Vitro. International Journal of Molecular Sciences. 2025;26(6):2376. doi:10.3390/ijms26062376
BibTeX
@article{Maek2025,
author = {Małek, Agata and Strzemski, Maciej and Kapka-Skrzypczak, Lucyna and Kurzepa, Jacek},
title = {Anticancer Activity of Melittin-Containing Bee Venom Fraction Against Glioblastoma Cells In Vitro},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {6},
pages = {2376},
doi = {10.3390/ijms26062376}
}
EUVIMED